ACAD
30.43
+0.34
+1.13%
AEMD
2.06
+0.01
+0.49%
APRI
1.08
-0.02
-1.82%
ARNA
24.05
+0.47
+1.99%
ATEC
1.725
-0.065
-3.631%
CNAT
6.04
0.00
0.00%
CRXM
0.169
0.00
0.00%
CYTX
1.11
-0.01
-0.89%
DXCM
69.52
-0.49
-0.70%
GNMK
12.05
-0.21
-1.71%
HALO
13.53
+0.27
+2.04%
ILMN
172.75
+0.78
+0.45%
INNV
0.116
-0.005
-4.132%
INO
6.01
0.00
0.00%
ISCO
1.23
-0.1
-7.52%
ISIS
57.56
0.00
0.00%
LGND
123.05
+2.36
+1.96%
LPTN
2.93
-2.93
-100.00%
MBVX
0.96
+0.03
+3.23%
MEIP
3.02
-0.05
-1.63%
MNOV
5.43
+0.12
+2.26%
MRTX
4.9
+0.25
+5.38%
MSTX
0.131
-0.007
-5.278%
NBIX
47.07
-0.72
-1.51%
NUVA
79.92
-1.19
-1.47%
ONCS
1.08
-0.04
-3.57%
ONVO
2.37
+0.05
+2.16%
OREX
2.47
-0.13
-5.00%
OTIC
18.9
+0.15
+0.80%
QDEL
37.71
-0.02
-0.05%
RCPT
231.96
0.00
0.00%
RGLS
0.98
+0.1
+11.36%
RMD
77
-1.03
-1.32%
SCIE
0
0.00
-14.2857%
SPHS
2.07
0.00
0.00%
SRNE
2.05
0.00
0.00%
TROV
0.96
-0.03
-3.03%
VICL
2.66
+0.01
+0.37%
VOLC
18
0.00
0.00%
ZGNX
13.4
-0.2
-1.47%
ACAD
30.43
+0.34
+1.13%
AEMD
2.06
+0.01
+0.49%
APRI
1.08
-0.02
-1.82%
ARNA
24.05
+0.47
+1.99%
ATEC
1.725
-0.065
-3.631%
CNAT
6.04
0.00
0.00%
CRXM
0.169
0.00
0.00%
CYTX
1.11
-0.01
-0.89%
DXCM
69.52
-0.49
-0.70%
GNMK
12.05
-0.21
-1.71%
HALO
13.53
+0.27
+2.04%
ILMN
172.75
+0.78
+0.45%
INNV
0.116
-0.005
-4.132%
INO
6.01
0.00
0.00%
ISCO
1.23
-0.1
-7.52%
ISIS
57.56
0.00
0.00%
LGND
123.05
+2.36
+1.96%
LPTN
2.93
-2.93
-100.00%
MBVX
0.96
+0.03
+3.23%
MEIP
3.02
-0.05
-1.63%
MNOV
5.43
+0.12
+2.26%
MRTX
4.9
+0.25
+5.38%
MSTX
0.131
-0.007
-5.278%
NBIX
47.07
-0.72
-1.51%
NUVA
79.92
-1.19
-1.47%
ONCS
1.08
-0.04
-3.57%
ONVO
2.37
+0.05
+2.16%
OREX
2.47
-0.13
-5.00%
OTIC
18.9
+0.15
+0.80%
QDEL
37.71
-0.02
-0.05%
RCPT
231.96
0.00
0.00%
RGLS
0.98
+0.1
+11.36%
RMD
77
-1.03
-1.32%
SCIE
0
0.00
-14.2857%
SPHS
2.07
0.00
0.00%
SRNE
2.05
0.00
0.00%
TROV
0.96
-0.03
-3.03%
VICL
2.66
+0.01
+0.37%
VOLC
18
0.00
0.00%
ZGNX
13.4
-0.2
-1.47%
Home » Archive by Category

Xconomy

FDA: Keytruda Now OK For Some Patients With Untreated Lung Cancer

October 24, 2016 – 9:17 pm

The FDA has approved the use of pembrolizumab (Keytruda) for some previously untreated patients with a certain type of lung cancer, the drug’s owner Merck (NYSE: MRK) announced late Monday….

[[Click headline to continue reading.]]

Bio Roundup: Jenkins Gets Mad, Bernie Gets His Pen, CRISPR IPO & J-Lo

October 21, 2016 – 3:30 am

If you’re among those frustrated by the lack of talk about health and science in the three presidential debates, this week perhaps brought you a wee consolation prize. The steady drip of hacked…

[[Click headline to continue reading.]]

BlackThorn Emerges With $40M, New Weapons Against Neuro Disorders

October 20, 2016 – 5:55 am

For three years, a group of investors and experienced neuroscience executives have been stealthily advancing one of the more ambitious new startups in neurology, called BlackThorn Therapeutics. Today…

[[Click headline to continue reading.]]

Arterys, GE Healthcare to Roll Out Next-Gen MRI Scans of Heart

October 19, 2016 – 10:09 am

The healthcare tools of the future often start as research projects in academic medical centers, but they may not break out into widespread clinical practice until some sort of logjam gives way to…

[[Click headline to continue reading.]]

All In One Place: A New Immuno-Oncology Trial Resource

October 19, 2016 – 7:00 am

More than 100 years ago, New York bone surgeon William Coley began to suspect that bacterial infections might be improving the outlook for patients also suffering from cancer. The infections were…

[[Click headline to continue reading.]]

The Power of the Cloud for Life Science R&D

October 19, 2016 – 5:43 am

“In the new world, it is not the big fish which eats the small fish, it’s the fast fish which eats the slow fish…” — Klaus Schwab, Founder/Executive Chairman, World…

[[Click headline to continue reading.]]

After “Hubris” and Its HCV Collapse, Can Vertex Avoid Same Mistakes?

October 18, 2016 – 3:50 am

Five years ago, in November 2011, a company from Princeton, NJ, called Pharmasset shared news that would have an impact on millions of people around the world with hepatitis C. Its experimental drug…

[[Click headline to continue reading.]]

Ex-Celgene Dealmaker Tom Daniel Charts a New Course Advising Biotechs

October 17, 2016 – 3:50 am

For close to a decade, Tom Daniel and George Golumbeski comprised perhaps one of the best-known dealmaking duos in biopharma, striking a slew of alliances that established Summit, NJ-based Celgene as…

[[Click headline to continue reading.]]

Bio Roundup: Bristol & Illumina Blues, Sickle Cell News & More

October 14, 2016 – 6:00 am

On Aug. 4, shares of Bristol-Myers Squibb closed at $75.32. Today, shares are worth just over $50. That means in three months, Bristol has lost a third of its value, equivalent to about $40 billion…

[[Click headline to continue reading.]]

Life Science Leaders Who Feel the Right Kind of Fear

October 12, 2016 – 3:00 am

In the world of betting on the future, life sciences find themselves in a storm, with huge opportunities, like CRISPR gene editing, and immense obstacles, such as soaring drug prices, that call for…

[[Click headline to continue reading.]]